Version 4.0.200811

MES-SA/Dx-5 (human, Caucasian, uterus, sarcoma)

Available in the following LABORATORY:

• Part of the Business Division of the Health Protection Agency (ECACC, Salisbury, Wiltshire)
  McCoy's 5a + 2mM Glutamine + 10% Fetal Bovine Serum (FBS). Split confluent cultures 1:6 to 1:8 i.e. seeding at 1-3 x 10,000 cells/cm2 using 0.03% EDTA; 5% CO2; 37C. (Tap side of flask with hand to dislodge cells).
  Passages: 46; Karyotype: Modal No 47 (parent line MES-SA-45). Reported karyotype 47,XX,12qt,22q-t(5q,6p),-3,-4,-7,+t(3q?,7q),Mar1,+mar2,+Mar3
  The multi drug-resistant cell line MES-SA/Dx5 was derived from the human uterine sarcoma cell line MES-SA which was originally obtained from a tumour from a 56-year-old Caucasian female at the time of hysterectomy. The Dx5 variant exhibits a 100-fold resistance to doxorubicin and has a reported doubling time of 30 hours. The two additional marker chromosomes indicate clonal selection during drug selection. MES-SA/Dx-5 cells exhibit marked cross-resistance to a number of chemotherapeutic agents (including daunorubicin, dactinomycin, vincristine, taxol, colchicine) and moderate cross-resistance to mitomycin C and melphalan. Cross resistance to bleomycin, cisplatin, carmustine, 5-fluorouracil or methotrexate was not observed.
  Research council deposit: No; Price Code: C;
  Validated by: isoenzymes (species confirmation)
  

Availability in cell line catalogues: ATCC: CRL 1977

Bibliographic references:

• Cancer Res 1983;43:4943-4950 - PMID: 6883344
  
• ibid 1985;45:4091